相关实验视频

Updated: Jun 5, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

修改后的格拉斯哥预后评分 (mGPS) 可以指导免疫疗法治疗的决策,超越进展

Jonas Saal¹, Markus Eckstein², Manuel Ritter³

¹Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn (UKB), Germany; Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.

European journal of cancer (Oxford, England : 1990)

|December 11, 2024

概括

修改后的格拉斯哥预后评分 (mGPS) 可以识别可能受益于免疫检查点抑制剂 (ICI) 治疗超出进展 (TBP) 的患者. 这种生物标志物有助于选择患者在疾病进展后继续治疗.

科学领域:

在瘤学瘤学.
临床生物标志物临床生物标志物
癌症治疗方法癌症治疗方法

背景情况:

治疗超越进展 (TBP) 是接受免疫检查点抑制剂 (ICI) 的患者的常见策略.
目前,没有经过验证的生物标志物可以预测哪些患者将从TBP中受益.
修改后的格拉斯哥预后分数 (mGPS) 是一个潜在的预后生物标志物.

研究的目的:

调查mGPS作为预测生物标志物的实用性,用于选择TBP的患者.
评估ICI治疗患者的mGPS和进展后生存率 (PPOS) 之间的关联.

主要方法:

对参与ICI治疗的患者进行的第三期试验 (IMmotion151,OAK,IMvigor211) 的后期分析.
在疾病进展时评估mGPS (PD-mGPS) 基于C反应蛋白和白蛋白水平.
不同PD-mGPS风险组和治疗策略之间的PPOS比较.

主要成果:

在所有三项试验中,PD-mGPS都表现出强大的预后价值,高风险的PD-mGPS与明显更短的PPOS相关.
低风险PD-mGPS组的患者从ICI-TBP中受益,而不是转向进一步线路治疗.
在中等/高风险PD-mGPS组中没有观察到ICI-TBP的显著益处.

结论:

在放射性PD测量的mGPS可以识别出具有更好的预后的患者,他们可能会从持续的阿特佐利祖马布治疗中受益.
mGPS可以帮助临床选择患者进行治疗后的进展.
这种生物标志物可能有助于优化接受ICI的患者的治疗策略.

关键词:

生物标志物生物标志物免疫治疗是一种免疫疗法.肺癌是一种肺癌.细胞癌是细胞癌.泌尿器癌症泌尿器癌症是什么

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.